无输血依赖时间（TWiTR）：基于3期SIMPLIFY-1、SIMPLIFY-2和MOMENTUM试验，将生存质量纳入骨髓纤维化治疗策略

IF 1.2

EJHaem Pub Date : 2025-06-18 DOI:10.1002/jha2.70075

Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik

{"title":"无输血依赖时间（TWiTR）：基于3期SIMPLIFY-1、SIMPLIFY-2和MOMENTUM试验，将生存质量纳入骨髓纤维化治疗策略","authors":"Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik","doi":"10.1002/jha2.70075","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life. Red blood cell transfusions form the basis of anemia management in myelofibrosis but dependence on transfusions is further associated with poorer survival and quality of life.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Time without transfusion reliance (TWiTR), a method integrating transfusion dependence and survival quality, was applied to three Phase 3 trials of momelotinib in myelofibrosis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>TWiTR demonstrated that patients treated with momelotinib versus comparators spent more time free from transfusions and anemia events.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Momelotinib may lead to improved survival quality for patients with myelofibrosis.</p>\n </section>\n \n <section>\n \n <h3> Trial registration</h3>\n \n <p>ClinicalTrials.gov identifiers: NCT01969838, NCT02101268, and NCT04173494</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 3","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70075","citationCount":"0","resultStr":"{\"title\":\"Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials\",\"authors\":\"Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik\",\"doi\":\"10.1002/jha2.70075\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life. Red blood cell transfusions form the basis of anemia management in myelofibrosis but dependence on transfusions is further associated with poorer survival and quality of life.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Time without transfusion reliance (TWiTR), a method integrating transfusion dependence and survival quality, was applied to three Phase 3 trials of momelotinib in myelofibrosis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>TWiTR demonstrated that patients treated with momelotinib versus comparators spent more time free from transfusions and anemia events.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Momelotinib may lead to improved survival quality for patients with myelofibrosis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial registration</h3>\\n \\n <p>ClinicalTrials.gov identifiers: NCT01969838, NCT02101268, and NCT04173494</p>\\n </section>\\n </div>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":\"6 3\",\"pages\":\"\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70075\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70075\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70075","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

骨髓纤维化的特点是虚弱的体质症状和贫血，这对生存和生活质量产生负面影响。红细胞输注是骨髓纤维化患者贫血管理的基础，但对输注的依赖与较差的生存率和生活质量进一步相关。方法将无输血依赖时间（TWiTR）作为一种综合输血依赖和生存质量的方法，应用于莫米洛替尼治疗骨髓纤维化的3个3期试验。结果：TWiTR表明，与比较组相比，接受莫米洛替尼治疗的患者在无输血和贫血事件方面的时间更长。结论莫米洛替尼可提高骨髓纤维化患者的生存质量。临床试验注册：ClinicalTrials.gov标识符：NCT01969838、NCT02101268和NCT04173494

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials

查看原文本刊更多论文

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials

Introduction

Myelofibrosis is characterized by debilitating constitutional symptoms and anemia, which negatively impact survival and quality of life. Red blood cell transfusions form the basis of anemia management in myelofibrosis but dependence on transfusions is further associated with poorer survival and quality of life.

Methods

Time without transfusion reliance (TWiTR), a method integrating transfusion dependence and survival quality, was applied to three Phase 3 trials of momelotinib in myelofibrosis.